Loading...

Intellectia LogoIntellectia
AI Trading Bot
Features
Markets
News
Resources
Pricing
Get Started
  1. Home
  2. Stock
  3. MMSI
MMSI logo

MMSI Overview

-
$
0.000
0.000(0.000%)
At close
0.000(0.000%)Aft-market
ET
$
0.000
0.000(0.000%)
At close
0.000(0.000%)Aft-market
ET
OverviewStock Price PredictionTechnicalValuationFinancialsEarningsShould I BuyNews & Events
an image of Intellectia Logoan image of Intellectia

Most Trusted AI Platform for Winning Trades

TwitterYoutubeQuoraDiscordLinkedinTelegram

Copyright © 2026 Intellectia.AI. All Rights Reserved.

Company

  • Home
  • Contact
  • About Us
  • Press
  • Privacy
  • Terms of Service
  • Service Terms of Use

Resources

  • Blog
  • Tutorial
  • Help Center
  • Affiliate Program

Markets

  • Market Analysis
  • Crypto
  • Featured Screeners
  • AI Earnings Calendar
  • Market Movers
  • Stock Monitor
  • Economic Calendar
  • All US Stocks
  • All Cryptos

Tools

  • Dividend Calculator
  • Dividend Yield Calculator
  • Options Profit Calculator

Features

  • QuantAI Alpha Pick
  • SwingMax Portfolio
  • Swing Trading
  • AI Stock Picker
  • Whales Auto Tracker
  • Daytrading Center
  • Patterns Detection
  • AI Screener
  • Financial AI Agent
  • Backtesting Playground
  • AI Earnings Prediction
  • Stock Monitor
  • Technical Analysis

News

  • Overview
  • Top News
  • Daily Market Brief
  • Earnings Analysis
  • Newswire
  • Stock News
  • Crypto News
  • Institution News
  • Congress News
  • Monitor News

Compare

  • TradingView
  • SeekingAlpha
Intellectia

Loading chart...

High
68.260
Open
67.430
VWAP
67.63
Vol
880.32K
Mkt Cap
4.04B
Low
66.940
Amount
59.53M
EV/EBITDA(TTM)
13.31
Total Shares
59.65M
EV
4.24B
EV/OCF(TTM)
14.25
P/S(TTM)
2.61
Merit Medical Systems, Inc. is engaged in the development, manufacture, and distribution of medical devices used in interventional, diagnostic, and therapeutic procedures in cardiology, radiology, oncology, critical care, and endoscopy. Its cardiovascular segment consists of four product categories: peripheral intervention, cardiac intervention, custom procedural solutions, and original equipment manufacturer. Its endoscopy segment consists of gastroenterology and pulmonology devices which assist in the palliative treatment of expanding esophageal, tracheobronchial and biliary strictures caused by malignant tumors. Its product portfolio of medical devices and accessories is used in lead management procedures for patients who need a pacemaker, or an implantable cardioverter-defibrillator lead removed or replaced. Its products are used in clinical areas, such as radiology, electrophysiology and more. It also manufactures hemostatic devices under the brand names StatSeal and WoundSeal.
Show More

Events Timeline

(ET)
2026-04-30
16:21:00
Company Narrows FY26 Revenue View to $1.612B-$1.634B
select
2026-04-30
16:21:00
Merit Q1 Revenue Exceeds Expectations at $381.9M
select

News

Yahoo Finance
6.5
06-05Yahoo Finance
Analysis of Three Stocks Capturing Wall Street's Attention
  • Covista's Dismal Outlook: Covista (CVSA) has shown a lackluster annual revenue growth of only 15.2% over the past five years, indicating a loss of competitive ground, with a projected 3.8 percentage point decline in free cash flow margin next year reflecting increased investments to defend its market position; the current stock price of $123.04 implies a forward P/E ratio of 14.4x, suggesting potential overvaluation.
  • Merit Medical's Challenges: Merit Medical Systems (MMSI) has a modest revenue base of $1.54 billion, which limits its fixed cost leverage and distribution channels, resulting in below-average returns on capital; trading at $60.64 per share with a forward P/E of 14.8x indicates management's struggle to find compelling investment opportunities.
  • Ally Financial's Growth Struggles: Ally Financial (ALLY) has experienced a mere 2.7% annual revenue growth over the past two years, significantly slower than its financial peers, and despite revenue growth, its earnings per share have declined by 4.8% annually; with a high net-debt-to-EBITDA ratio of 8x, the company may face challenges raising capital under unfavorable terms, trading at $40.99 per share with a forward P/E of 7.5x, indicating financial health concerns.
  • Market Environment Shift: The rapid market changes are accelerating the separation of quality stocks from overvalued ones, with AI technologies swiftly impacting various sectors, prompting investors to stay alert to market dynamics to identify potential investment opportunities.
Newsfilter
5.0
05-19Newsfilter
Merit Medical Elects Scott Ward to Board of Directors
  • New Board Member: Merit Medical elected Scott Ward to its Board of Directors during the annual shareholder meeting for a three-year term, reflecting the company's emphasis on diverse and experienced leadership.
  • Extensive Industry Experience: With over 40 years in the medical device sector, including senior roles at Medtronic, Ward is expected to significantly impact Merit's strategic development and growth trajectory.
  • Committee Appointments: Ward has been appointed to the Governance and Sustainability and Finance and Operating Committees, underscoring the company's trust in his strategic insights and decision-making capabilities.
  • Commitment to Innovation: Ward expressed respect for Merit's dedication to innovation and patient service, indicating that his contributions will likely enhance the company's long-term growth and market expansion efforts.
Fool
5.0
05-17Fool
Merit Medical Executive's Share Sale Raises Concerns
  • Executive Share Sale: Lynne N. Ward, a director at Merit Medical Systems, sold 5,000 shares in an open market transaction valued at approximately $313,000, indicating a significant reduction in her ownership, with direct holdings decreasing by 39% from 12,809 shares to 7,809 shares.
  • Transaction Impact Analysis: This sale marks Ward's only open-market transaction in the past year, reflecting a continued reduction in her holdings, and comes at a time when Merit Medical's stock hit a 52-week low of $59.74 on May 12, raising concerns about the company's growth prospects amid macroeconomic pressures.
  • Company Financial Overview: Merit Medical Systems reported a trailing twelve-month revenue of $1.54 billion and a net income of $139.34 million, with a workforce of 7,400 employees; despite facing macroeconomic challenges, the company's focus on innovation and procedural efficiency remains a key competitive advantage in the medical device sector.
  • Investor Concerns: Following the sale, Ward retains 7,809 shares, suggesting confidence in the company's long-term outlook, even as the sales guidance shows only a slight increase over the previous year, indicating potential growth deceleration that investors should monitor closely.
Newsfilter
1.0
05-08Newsfilter
Merit Medical to Participate in 2026 Bank of America Health Care Conference
  • Conference Participation: Merit Medical will participate in the Bank of America Health Care Conference from May 12-14, 2026, with management scheduled for a fireside chat on May 12 at 3:00 PM PT, highlighting the company's leadership in healthcare technology.
  • Live Webcast: The fireside chat will be accessible via the company's investor relations website, allowing global investors to stay updated on the latest developments, which is expected to enhance investor interest and confidence in the company.
  • Company Background: Founded in 1987, Merit Medical specializes in the development, manufacturing, and distribution of proprietary medical devices used in interventional, diagnostic, and therapeutic procedures, particularly impacting cardiology, radiology, and oncology.
  • Global Team: With over 800 sales and clinical support personnel and approximately 7,600 employees worldwide, Merit Medical demonstrates strong operational capabilities and market reach in the global medical device sector.
seekingalpha
9.5
05-01seekingalpha
Merit Medical Systems Reports Strong Q1 2026 Earnings and Strategic Acquisition
  • Revenue Growth: Merit Medical reported total revenue of $381.9 million in Q1 2026, reflecting a 7% year-over-year increase, with U.S. sales up 6.8% and international sales up 3%, indicating robust market performance.
  • Acquisition Expansion: The company acquired View Point Medical for $140 million, with $90 million paid in cash, which is expected to triple the annual addressable procedure opportunity for its oncology business, enhancing competitive positioning.
  • Profitability Improvement: Q1 net income reached $56.7 million, or $0.94 per share, exceeding guidance by $3.7 million, while the non-GAAP operating margin hit 19.7%, marking the highest in the company's history and reflecting effective management execution.
  • Future Outlook: The company anticipates total revenue growth of 6.3% to 7.8% for 2026, with non-GAAP EPS projected between $4.01 and $4.15, demonstrating confidence in future growth despite facing tariff and geopolitical risks.
Newsfilter
9.5
04-02Newsfilter
Merit Medical Systems to Release Q1 2026 Financial Results
  • Earnings Release Schedule: Merit Medical Systems plans to announce its financial results for the quarter ending March 31, 2026, after market close on April 30, 2026, demonstrating the company's commitment to transparency and investor communication.
  • Investor Conference Call: On the same day, Merit will hold an investor conference call at 4:30 p.m. Eastern Time, aimed at sharing financial results and addressing investor inquiries, thereby enhancing investor confidence.
  • Company Background: Founded in 1987, Merit focuses on the development, manufacturing, and distribution of proprietary medical devices used in interventional, diagnostic, and therapeutic procedures, particularly in cardiology, radiology, and oncology, showcasing its expertise in healthcare technology.
  • Global Workforce: Merit employs approximately 7,600 people worldwide, supported by a domestic and international sales force and clinical support team of over 800 individuals, indicating its extensive reach and service capabilities in the global market.
Wall Street analysts forecast MMSI stock price to rise
8 Analyst Rating
Wall Street analysts forecast MMSI stock price to rise
7 Buy
1 Hold
0 Sell
Strong Buy
Current: 0.000
sliders
Low
90.00
Averages
104.63
High
122.00
Current: 0.000
sliders
Low
90.00
Averages
104.63
High
122.00
JPMorgan
Overweight
downgrade
$95 -> $77
AI Analysis
2026-05-01
Reason
JPMorgan
Price Target
$95 -> $77
AI Analysis
2026-05-01
downgrade
Overweight
Reason
JPMorgan lowered the firm's price target on Merit Medical to $77 from $95 and keeps an Overweight rating on the shares.
Baird
David Rescott
Outperform
to
Outperform
downgrade
$92 -> $83
2026-05-01
Reason
Baird
David Rescott
Price Target
$92 -> $83
2026-05-01
downgrade
Outperform
to
Outperform
Reason
Baird analyst David Rescott lowered the firm's price target on Merit Medical to $83 from $92 and keeps an Outperform rating on the shares. The firm updated its model following encouraging upside Q1 results nut where theback-end growth ramp likeely weighs on the shares until the second half of the year.
Unlock Full Analyst Thesis, Get the complete breakdown of rating reason for MMSI
Unlock Now

Valuation Metrics

The current forward P/E ratio for Merit Medical Systems Inc (MMSI.O) is 17.01, compared to its 5-year average forward P/E of 24.98. For a more detailed relative valuation and DCF analysis to assess Merit Medical Systems Inc's fair value, Click here.

Forward PE

The forward P/E ratio is a valuation metric that divides a company's current stock price by its estimated future earnings per share over the next 12 months.
StronglyUndervaluedUndervaluedFairOvervaluedStronglyOvervalueddotted line Image
5Y Average PE
24.98
Current PE
17.01
Overvalued PE
28.61
Undervalued PE
21.35

Forward EV/EBITDA

The forward EV/EBITDA ratio is a valuation metric that divides a company's enterprise value (EV) by its estimated future earnings before interest, taxes, depreciation, and amortization (EBITDA) over the next 12 months.
StronglyUndervaluedUndervaluedFairOvervaluedStronglyOvervalueddotted line Image
5Y Average EV/EBITDA
17.20
Current EV/EBITDA
12.96
Overvalued EV/EBITDA
19.39
Undervalued EV/EBITDA
15.01

Forward PS

The forward P/S ratio is a valuation metric that divides a company's current stock price by its estimated future sales (or revenue) per share over the next 12 months.
StronglyUndervaluedUndervaluedFairOvervaluedStronglyOvervalueddotted line Image
5Y Average PS
3.31
Current PS
2.32
Overvalued PS
3.78
Undervalued PS
2.85

Financials

AI Analysis
Annual
Quarterly

Whales Holding MMSI

O
Oberweis Asset Management, Inc.
Holding
MMSI
+42.94%
3M Return
A
Alaska Permanent Fund
Holding
MMSI
+16.30%
3M Return
A
Aristotle Capital Boston, LLC
Holding
MMSI
+12.89%
3M Return
M
Maverick Capital, Ltd.
Holding
MMSI
+12.67%
3M Return
F
Fuller & Thaler Asset Management, Inc.
Holding
MMSI
+12.61%
3M Return
C
Conestoga Capital Advisors, LLC
Holding
MMSI
+11.46%
3M Return

Trading Trends

    Insider
    Hedge Fund
    Congress Trading

People Also Watch

Frequently Asked Questions

What is Merit Medical Systems Inc (MMSI) stock price today?

The current price of MMSI is 67.68 USD — it has increased 1.11

What is Merit Medical Systems Inc (MMSI)'s business?

Merit Medical Systems, Inc. is engaged in the development, manufacture, and distribution of medical devices used in interventional, diagnostic, and therapeutic procedures in cardiology, radiology, oncology, critical care, and endoscopy. Its cardiovascular segment consists of four product categories: peripheral intervention, cardiac intervention, custom procedural solutions, and original equipment manufacturer. Its endoscopy segment consists of gastroenterology and pulmonology devices which assist in the palliative treatment of expanding esophageal, tracheobronchial and biliary strictures caused by malignant tumors. Its product portfolio of medical devices and accessories is used in lead management procedures for patients who need a pacemaker, or an implantable cardioverter-defibrillator lead removed or replaced. Its products are used in clinical areas, such as radiology, electrophysiology and more. It also manufactures hemostatic devices under the brand names StatSeal and WoundSeal.

What is the price predicton of MMSI Stock?

Wall Street analysts forecast MMSI stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for MMSI is104.63 USD with a low forecast of 90.00 USD and a high forecast of 122.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.

What is Merit Medical Systems Inc (MMSI)'s revenue for the last quarter?

Merit Medical Systems Inc revenue for the last quarter amounts to 381.88M USD, increased 7.46

What is Merit Medical Systems Inc (MMSI)'s earnings per share (EPS) for the last quarter?

Merit Medical Systems Inc. EPS for the last quarter amounts to 0.68 USD, increased 38.78

How many employees does Merit Medical Systems Inc (MMSI). have?

Merit Medical Systems Inc (MMSI) has 7500 emplpoyees as of June 17 2026.

What is Merit Medical Systems Inc (MMSI) market cap?

Today MMSI has the market capitalization of 4.04B USD.